

## COMPOUNDED DRUG TESTING REPORT

In 2003 the Board initiated a program to test drug preparations compounded by pharmacies. All preparations are tested for potency and, if applicable, sterility and endotoxins. The tables listed below are for the fiscal year ending June 30, 2008.

Dosage Form	Tests Performed
Capsule	56
Inhalation solution	1
Injection	2
I.V. solution	12
Ophthalmic solution	1
Oral solution	1
Oral suspension	87
Powder	7
Suppository	14
Transdermal	1
Troche	4

Test Results	Tests Performed	Percentage
Satisfactory	140	75.3%
Unsatisfactory	46	24.7%
<b>Total</b>	186	100%

All unsatisfactory results were related to potency failures. An acceptable potency range is considered +/- 10% of the expected potency, unless a U.S.P. monograph states a different range for a specific preparation. Failing potency results ranged from 21.3% to 373.7%. Pharmacies are notified of unsatisfactory results and asked to complete a quality assurance review of their compounding practices and provide a corrective action plan.

Drugs with Unsatisfactory Results	
A-B-H-R suppositories	Lansoprazole oral suspension
Amlodipine capsules	Levothyroxine capsules
Amoxicillin capsules	Methyltestosterone capsules
Baclofen suppositories	Metronidazole oral suspension
Biest/Progesterone capsules	Omeprazole oral suspension
Biest/Testosterone capsules	Piroxicam capsules
Biest/Progesterone/DHEA capsules	Progesterone suppositories
Captopril oral suspension	Rifampin oral suspension
DES capsules	Sulfapyridine capsules
DHEA capsules	T-4 Aliquot powder
D-M-D suppositories	Tetracaine lollipops
Enalapril oral suspension	Triest/Progesterone capsules
Estradiol capsules	Triest/Progesterone troches
Gentamicin in D-5-W IV solution	Triest/Progesterone/Testosterone/DHEA capsules
HHR capsules	Ursodiol oral suspension